Wall Street analysts expect that GenMark Diagnostics, Inc (NASDAQ:GNMK) will announce earnings per share of ($0.19) for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for GenMark Diagnostics’ earnings, with the highest EPS estimate coming in at ($0.18) and the lowest estimate coming in at ($0.20). GenMark Diagnostics reported earnings of ($0.20) per share during the same quarter last year, which indicates a positive year over year growth rate of 5%. The firm is expected to issue its next quarterly earnings results on Monday, November 4th.

On average, analysts expect that GenMark Diagnostics will report full year earnings of ($0.80) per share for the current fiscal year, with EPS estimates ranging from ($0.81) to ($0.78). For the next financial year, analysts forecast that the business will report earnings of ($0.52) per share, with EPS estimates ranging from ($0.61) to ($0.40). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that that provide coverage for GenMark Diagnostics.

GenMark Diagnostics (NASDAQ:GNMK) last released its quarterly earnings data on Monday, August 5th. The medical equipment provider reported ($0.23) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.02). The company had revenue of $18.37 million for the quarter, compared to analyst estimates of $17.92 million. GenMark Diagnostics had a negative return on equity of 167.54% and a negative net margin of 63.86%.

GNMK has been the topic of several analyst reports. BidaskClub lowered GenMark Diagnostics from a “sell” rating to a “strong sell” rating in a report on Tuesday, July 23rd. Canaccord Genuity reissued a “buy” rating and issued a $10.00 price objective on shares of GenMark Diagnostics in a report on Monday, July 1st. Finally, Zacks Investment Research lowered shares of GenMark Diagnostics from a “hold” rating to a “sell” rating in a report on Thursday, June 13th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $9.67.

In other GenMark Diagnostics news, insider Hany Massarany sold 8,080 shares of the firm’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $6.25, for a total transaction of $50,500.00. Following the completion of the sale, the insider now owns 816,871 shares of the company’s stock, valued at $5,105,443.75. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Kevin C. Oboyle sold 18,350 shares of the firm’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $6.51, for a total value of $119,458.50. Following the sale, the director now directly owns 102,112 shares of the company’s stock, valued at approximately $664,749.12. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 57,847 shares of company stock worth $359,859. Corporate insiders own 5.24% of the company’s stock.

Several institutional investors have recently made changes to their positions in GNMK. Susquehanna International Group LLP purchased a new position in shares of GenMark Diagnostics during the 2nd quarter worth $131,000. Nuveen Asset Management LLC acquired a new stake in shares of GenMark Diagnostics during the 2nd quarter worth about $2,700,000. UBS Asset Management Americas Inc. increased its position in shares of GenMark Diagnostics by 22.4% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 51,946 shares of the medical equipment provider’s stock worth $337,000 after purchasing an additional 9,519 shares during the last quarter. Morgan Stanley raised its holdings in GenMark Diagnostics by 434.0% in the 2nd quarter. Morgan Stanley now owns 1,824,449 shares of the medical equipment provider’s stock valued at $11,841,000 after buying an additional 1,482,787 shares during the period. Finally, AQR Capital Management LLC raised its holdings in GenMark Diagnostics by 257.5% in the 2nd quarter. AQR Capital Management LLC now owns 42,210 shares of the medical equipment provider’s stock valued at $274,000 after buying an additional 30,403 shares during the period. 91.03% of the stock is currently owned by institutional investors and hedge funds.

Shares of GNMK traded up $0.30 during midday trading on Friday, reaching $6.12. The company had a trading volume of 318,453 shares, compared to its average volume of 339,452. GenMark Diagnostics has a 1-year low of $3.58 and a 1-year high of $8.37. The stock has a market cap of $337.74 million, a PE ratio of -6.73 and a beta of 1.29. The firm has a 50 day simple moving average of $6.23 and a 200-day simple moving average of $6.80. The company has a quick ratio of 2.83, a current ratio of 3.39 and a debt-to-equity ratio of 3.69.

GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.

See Also: Dead Cat Bounce

Get a free copy of the Zacks research report on GenMark Diagnostics (GNMK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.